# A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

> **NCT01287741** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 1418 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Obinutuzumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01287741
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07-26
- **Primary completion:** 2016-04-29
- **Final completion:** 2018-01-31
- **Target enrollment:** 1418 (ACTUAL)
- **Why stopped:** The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.
- **Last updated:** 2019-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287741, "A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01287741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*